- Home
- TRNR vs APRE Comparison
TRNR vs APRE Comparison
Compare TRNR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | APRE |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.9M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TRNR | APRE |
|---|---|---|
| Price | $1.09 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 101.7K | 77.2K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,774,000.00 | $488,239.00 |
| Revenue This Year | $249.54 | N/A |
| Revenue Next Year | $304.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.36 | N/A |
| 52 Week Low | $0.83 | $0.84 |
| 52 Week High | $39.60 | $4.65 |
Technical Indicators
Market Signals| Indicator | TRNR | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 30.76 | 41.29 |
| Support Level | $0.83 | $0.91 |
| Resistance Level | $1.50 | $1.02 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 28.99 | 44.44 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.